Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Good
|
|
New words:
abandonment, advice, aimed, asset, award, baseline, Brovana®for, Bush, choice, chosen, COBRA, counsel, dental, disability, display, divestiture, easily, estate, exceed, facilitate, FDAAA, hierarchy, hospital, Jeffrey, Kelly, Lexington, Likewise, logistical, margin, maximize, orderly, permanently, principle, prompt, rata, rental, restated, salary, satisfactory, Scott, Secretary, sublease, Townsend, Treasurer, ultimately, variation, Young
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 EX-10.1 Manufacturing and Supply Agreement Dated As of August 20, 2007 by and Among the Company, Jagotec Ag and Skyepharma PLC.
- 10.2 EX-10.2 First Amendment Dated November 5, 2007 to the Manufacturing Services Agreement by and Between Patheon Pharmaceuticals Inc. and the Company Dated May 9, 2007
- 10.4 EX-10.4 Amended and Restated Employment Agreement Dated November 5, 2007 by and Between the Company and Frank E. Thomas.
- 10.5 EX-10.5 Amended and Restated Employment Agreement Dated November 6, 2007 by and Between the Company and Trevor Phillips
- 10.6 EX-10.6 Amended and Restated Employment Agreement Dated November 6, 2007 by and Between the Company and Scott B. Townsend
- 10.7 EX-10.7 Amended and Restated Employment Agreement Dated November 5, 2007 by and Between the Company Jeffrey E. Young.
- 31.1 EX-31.1 Certification of the Principal Executive Officer Pursuant to Rule 13A-14(A) and 15D-14(A) of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-oxley Act
- 31.2 EX-31.2 Section 302 Certification of the Principal Financial Officer Pursuant to Rule 13A-14(A) and 15D-14(A) of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbane
- 32.1 EX-32.1 Section 906 Certification of the Principal Executive Officer Pursuant to 18 U.s.c. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
- 32.2 EX-32.2 Section 906 Certification of the Principal Financial Officer Pursuant to 18 U.s.c. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
Related press release
CRTX similar filings
Filing view
External links
EXHIBIT 32.2
CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER
PURSUANT TO RULE 13a-14(b) OF
THE SECURITIES EXCHANGE ACT OF 1934 AND 18 U.S.C. SECTION 1350
PURSUANT TO RULE 13a-14(b) OF
THE SECURITIES EXCHANGE ACT OF 1934 AND 18 U.S.C. SECTION 1350
In connection with the Quarterly Report on Form 10-Q of Critical Therapeutics, Inc. (the “Company”) for the period ended September 30, 2007 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Thomas P. Kelly, Senior Vice President of Finance and Corporate Development and Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and | ||
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: November 8, 2007
| /s/ Thomas P. Kelly ———————————————————— Thomas P. Kelly Chief Financial Officer and Senior Vice President of Finance and Corporate Development (Principal Financial Officer) | ||||